^
    1d
    VIALE-M: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (clinicaltrials.gov)
    P3, N=112, Completed, AbbVie | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Feb 2026
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax) • Onureg (azacitidine oral)
    1d
    Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction (clinicaltrials.gov)
    P1/2, N=28, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1d
    How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers (clinicaltrials.gov)
    P1, N=8, Recruiting, Sumitomo Pharma America, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    enzomenib (DSP-5336)
    1d
    A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=12, Suspended, City of Hope Medical Center | Recruiting --> Suspended
    Trial suspension
    |
    Venclexta (venetoclax) • azacitidine
    1d
    Expanded Access to Vodobatinib for Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Not Responded to Previous Treatments (clinicaltrials.gov)
    P=N/A, N=0, Temporarily Not Available, Sun Pharma Advanced Research Company Limited
    New trial
    |
    vodobatinib (SCO - 088)
    1d
    First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) (clinicaltrials.gov)
    P1, N=78, Recruiting, Genmab | N=40 --> 78
    Enrollment change • Trial initiation date • First-in-human
    1d
    AARON: Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML (clinicaltrials.gov)
    P2, N=30, Completed, Ludwig-Maximilians - University of Munich | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • azacitidine • relatlimab (BMS-986016)
    1d
    Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • nemtabrutinib (MK-1026)
    1d
    Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. (clinicaltrials.gov)
    P1, N=46, Not yet recruiting, Arovella Therapeutics Ltd
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • ALA-101
    1d
    TAGALONG: Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (clinicaltrials.gov)
    P2, N=53, Recruiting, Joshua Zeidner | Trial completion date: Dec 2027 --> Jul 2031 | Trial primary completion date: Aug 2027 --> Jul 2030
    Trial completion date • Trial primary completion date
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)
    1d
    my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults (clinicaltrials.gov)
    P=N/A, N=143, Not yet recruiting, Dana-Farber Cancer Institute
    New trial
    2d
    Ponatinib inhibits LCK and PI3K signaling and promotes CD8+ T stem cell memory cell development. (PubMed, Nat Commun)
    Furthermore, ponatinib increases chimeric antigen receptor (CAR) TSCM cells by reducing CAR T cell exhaustion, resulting in durable antitumor efficacy. Our results thus implicate ponatinib as therapeutic immunomodulator, inducing TSCM cells for improved antitumor T cell activity.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD8 (cluster of differentiation 8) • TCF7 (Transcription Factor 7)
    |
    Iclusig (ponatinib)